vs
Comstock Holding Companies, Inc.（CHCI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Comstock Holding Companies, Inc.的1.3倍（$30.3M vs $23.9M），Comstock Holding Companies, Inc.净利率更高（56.3% vs -221.3%，领先277.6%），REGENXBIO Inc.同比增速更快（43.0% vs 41.5%），过去两年Comstock Holding Companies, Inc.的营收复合增速更高（50.0% vs 39.4%）
该条目原介绍康斯托克矿脉的地理与发现背景，并非企业经营信息，康斯托克控股公司是一家美国企业，相关公开经营业务信息暂缺。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CHCI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.9M
营收增速更快
RGNX
高出1.5%
41.5%
净利率更高
CHCI
高出277.6%
-221.3%
两年增速更快
CHCI
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.9M | $30.3M |
| 净利润 | $13.5M | $-67.1M |
| 毛利率 | 35.5% | — |
| 营业利润率 | 32.4% | -190.0% |
| 净利率 | 56.3% | -221.3% |
| 营收同比 | 41.5% | 43.0% |
| 净利润同比 | 30.5% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHCIRGNX
| Q4 25 | $23.9M | $30.3M | ||
| Q3 25 | $13.3M | $29.7M | ||
| Q2 25 | $13.0M | $21.4M | ||
| Q1 25 | $12.6M | $89.0M | ||
| Q4 24 | $16.9M | $21.2M | ||
| Q3 24 | $13.0M | $24.2M | ||
| Q2 24 | $10.8M | $22.3M | ||
| Q1 24 | $10.6M | $15.6M |
净利润CHCIRGNX
| Q4 25 | $13.5M | $-67.1M | ||
| Q3 25 | $541.0K | $-61.9M | ||
| Q2 25 | $1.4M | $-70.9M | ||
| Q1 25 | $1.6M | $6.1M | ||
| Q4 24 | $10.3M | $-51.2M | ||
| Q3 24 | $2.4M | $-59.6M | ||
| Q2 24 | $946.0K | $-53.0M | ||
| Q1 24 | $910.0K | $-63.3M |
毛利率CHCIRGNX
| Q4 25 | 35.5% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 33.4% | 70.2% | ||
| Q3 24 | 26.3% | 48.8% | ||
| Q2 24 | 17.2% | 52.5% | ||
| Q1 24 | 16.5% | 72.6% |
营业利润率CHCIRGNX
| Q4 25 | 32.4% | -190.0% | ||
| Q3 25 | 5.0% | -176.3% | ||
| Q2 25 | 13.7% | -296.3% | ||
| Q1 25 | 13.7% | 13.6% | ||
| Q4 24 | 30.1% | -242.1% | ||
| Q3 24 | 21.8% | -256.6% | ||
| Q2 24 | 11.4% | -251.3% | ||
| Q1 24 | 10.8% | -408.8% |
净利率CHCIRGNX
| Q4 25 | 56.3% | -221.3% | ||
| Q3 25 | 4.1% | -208.3% | ||
| Q2 25 | 11.1% | -331.8% | ||
| Q1 25 | 12.6% | 6.8% | ||
| Q4 24 | 61.1% | -241.3% | ||
| Q3 24 | 18.3% | -246.3% | ||
| Q2 24 | 8.8% | -237.7% | ||
| Q1 24 | 8.6% | -405.4% |
每股收益（稀释后）CHCIRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | $0.09 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $70.0M | $102.7M |
| 总资产 | $85.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHCIRGNX
| Q4 25 | $31.3M | $230.1M | ||
| Q3 25 | $26.2M | $274.2M | ||
| Q2 25 | $30.5M | $323.3M | ||
| Q1 25 | $28.3M | $267.9M | ||
| Q4 24 | $28.8M | $234.7M | ||
| Q3 24 | $21.1M | $255.5M | ||
| Q2 24 | $17.4M | $290.4M | ||
| Q1 24 | $16.2M | $338.7M |
股东权益CHCIRGNX
| Q4 25 | $70.0M | $102.7M | ||
| Q3 25 | $56.3M | $161.5M | ||
| Q2 25 | $55.5M | $213.7M | ||
| Q1 25 | $53.7M | $274.2M | ||
| Q4 24 | $52.4M | $259.7M | ||
| Q3 24 | $41.7M | $301.4M | ||
| Q2 24 | $39.2M | $348.3M | ||
| Q1 24 | $37.9M | $390.7M |
总资产CHCIRGNX
| Q4 25 | $85.0M | $453.0M | ||
| Q3 25 | $67.6M | $525.2M | ||
| Q2 25 | $65.2M | $581.0M | ||
| Q1 25 | $62.8M | $490.9M | ||
| Q4 24 | $64.9M | $466.0M | ||
| Q3 24 | $52.2M | $519.1M | ||
| Q2 24 | $48.6M | $569.4M | ||
| Q1 24 | $46.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 0.36× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CHCIRGNX
| Q4 25 | $4.8M | $-52.3M | ||
| Q3 25 | $-3.2M | $-56.0M | ||
| Q2 25 | $2.2M | $-49.3M | ||
| Q1 25 | $582.0K | $33.6M | ||
| Q4 24 | $10.7M | $-31.6M | ||
| Q3 24 | $3.9M | $-40.5M | ||
| Q2 24 | $1.3M | $-45.5M | ||
| Q1 24 | $-2.2M | $-55.5M |
自由现金流CHCIRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率CHCIRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度CHCIRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率CHCIRGNX
| Q4 25 | 0.36× | — | ||
| Q3 25 | -5.96× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.37× | 5.53× | ||
| Q4 24 | 1.03× | — | ||
| Q3 24 | 1.63× | — | ||
| Q2 24 | 1.35× | — | ||
| Q1 24 | -2.46× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHCI
| Related Party | $22.1M | 92% |
| Nonrelated Party | $1.9M | 8% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
